2/23/2012 | CVHYPF | Sangamo files $100 million shelf covering stock, debt and preferreds
|
11/16/2009 | SS | Sangamo Biosciences investor sells 135,039 shares, keeps 4.1% stake
|
5/26/2009 | SS | Sangamo Biosciences investor sells 206,105 shares, keeps 5.52% stake
|
3/5/2009 | CVHY | Sangamo Biosciences files $100 million shelf
|
9/5/2008 | SS | Kopp sells 183,350 shares of Sangamo Biosciences
|
9/13/2007 | SS | Kopp has 8.32% stake in Sangamo
|
7/17/2007 | PP | New Issue: Sangamo BioSciences announces $30 million stock placement
|
7/17/2007 | PP | Market Commentary: Sangamo sells $30 million of stock; GTL Resources arranges £13 million offering
|
11/16/2006 | BT | Sangamo keeps cash burn at a minimum as products move to phase 2 development
|
10/31/2006 | BT | Sangamo corrects net loss per share to $0.08 from $0.09
|
10/31/2006 | BT | JMP ups revenue estimate for Sangamo
|
10/30/2006 | BT | Sangamo ends third quarter with $2.8 million loss, $57 million of cash
|
9/28/2006 | BT | Sangamo kept at market outperform by JMP
|
9/18/2006 | BT | Sangamo data shows effectiveness of SB-509 in neuropathy
|
7/26/2006 | BT | Sangamo reiterated at market outperform by JMP
|
7/25/2006 | BT | Sangamo reports net loss of $3.3 million for the second quarter
|
6/28/2006 | BT | Sangamo says it will take diabetic neuropathy program into phase 2 clinical trials this year
|
6/16/2006 | BT | Market Commentary: Hollis-Eden stock jumps on positive preclinical data; Inspire to present results on cystic fibrosis drug
|
6/16/2006 | BT | New Issue: Sangamo prices $20.925 million follow-on offering at $6.75, discounted from $7.35 close
|
6/15/2006 | BT | Sangamo prices follow-on offering of 3.1 million shares via Piper Jaffray
|
6/13/2006 | BT | Sangamo reiterated at market outperform
|
6/12/2006 | BT | Sangamo presents 'encouraging' ZFP therapeutic data at diabetes meeting
|
5/26/2006 | BT | Sangamo preclinical data suggests SB-509 effective in treatment of diabetic neuropathy in animal model
|
5/26/2006 | BT | Sangamo Biosciences files $50 million stock, warrant shelf
|
5/2/2006 | BT | JMP reiterates Sangamo at market outperform
|
4/21/2006 | BT | JMP reiterates Sangamo at market outperform
|
4/7/2006 | BT | Sangamo reiterated at market outperform by Jefferies
|
4/6/2006 | BT | Sangamo phase 1 trial of SB-509 for diabetic neuropathy meets safety endpoints
|
3/2/2006 | BT | Sangamo licenses MaxCyte cell loading technology for HIV/AIDS program
|
2/10/2006 | BT | JMP reiterates Sangamo at market outperform
|
2/9/2006 | BT | Sangamo BioSciences develops means of creating HIV resistance
|
1/25/2006 | BT | Sangamo BioSciences study shows benefit of engineered ZFP in treatment of artery disease
|
1/18/2006 | BT | JMP says select small-, mid-cap biotech stocks look promising
|
1/12/2006 | BT | Sangamo plans phase 2 trial of ZFP to treat diabetic neuropathy
|
1/11/2006 | BT | JMP reiterates Sangamo at market outperform
|
1/4/2006 | BT | Pfizer, Sangamo expand collaboration on research of enhanced protein production
|
12/20/2005 | BT | JMP reiterates Sangamo at market outperform
|
12/19/2005 | BT | Sangamo says study shows ZFN therapy can make cells resistant to HIV
|
12/1/2005 | BT | Sangamo reiterated by JMP at market outperform
|
11/30/2005 | BT | Sangamo begins phase 1 trial of SB-509 in diabetic neuropathy
|
11/17/2005 | BTPP | Sangamo BioSciences drops $1 million placement of stock with director
|
11/16/2005 | BT | Sangamo reports ZFP Therapeutic has potential to treat congestive heart failure
|
11/14/2005 | PP | Market Commentary: Amkor prices $100 million of convertibles; UCN wraps $2.5 million stock offering
|
11/11/2005 | BT | Market Commentary: OSI Pharma, Eyetech lower; Coley steady after big net loss; King Pharma, Pain extend moves
|
11/11/2005 | PP | Market Commentary: Sangamo $20.5 million deal tops market activity in slow session; Titan tops Canada business
|
11/11/2005 | BTPP | New Issue: Sangamo BioSciences sells $20.5 million shares in direct placement
|
11/7/2005 | BT | Sangamo BioSciences' ZFP Therapeutic shows potential as treatment for neuropathic pain
|
10/31/2005 | BT | JMP reiterates Sangamo at market outperform
|
10/6/2005 | BT | JMP holds Sangamo at market outperform
|
10/3/2005 | BT | Sangamo maintained by JMP at market outperform
|
9/22/2005 | BT | Sangamo maintained by JMP at market outperform
|